TGNA:FRA
Transgene SA
0,67 €
arrow_downward
-0,59%(-0,0040) 1K
14-okt, 8:03:02 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoTGNA tikeri uchun statistika yaratilmoqda...
Ochish
0,67 €
Yuqori
0,67 €
Past
0,67 €
Bozor kapitali
193,04 mln
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
1,48 €
52 haftalik eng past
0,60 €
Aksiya boʻyicha daromad
-0,17 €
Xodimlar soni
152
Ochish
0,67 €
Yuqori
0,67 €
Past
0,67 €
Bozor kapitali
193,04 mln
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
1,48 €
52 haftalik eng past
0,60 €
Aksiya boʻyicha daromad
-0,17 €
Xodimlar soni
152
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
The Motley Fool
·
14 daqiqa oldin
Over 25% of the Stocks in the S&P 500 Are Down 40% or More. 4 Bargain Tech Stocks to Buy Now
ChartMill
·
36 daqiqa oldin
Discover which dow jones stocks are making waves on Wednesday.
The Northern Virginia Daily
·
26 daqiqa oldin
US stocks drop toward their worst day since July as inflation worsens
Seeking Alpha
·
1 soat oldin
Nasdaq tumbles 2%, and these 10 stocks have fueled the selloff
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Transgene SA haqida